Pcsk9
-
{
- All
- News
-
New Oral Pill Enlicitide Cuts 'Bad' Cholesterol By 60% In Landmark Trial
The new oral pill enlicitide cuts bad cholesterol risk by 60% in a new landmark trial. Here are the mechanisms behind it and why the oral pill could revolutionise cholesterol management.
-
New Experimental Drug Enlicitide May Cut "Bad" Cholesterol By Up To 60%
A new daily oral medication, enlicitide, has shown reductions in LDL cholesterol of up to 60% in a late-stage Phase 3 trial, matching the efficacy of injectable PCSK9 inhibitors.
-
Protein Linked to Heart Attack Identified
A protein that increases levels of LDL (low-density lipoprotein) cholesterol, also referred to as "bad" cholesterol, in the bloodstream is associated with heart attacks, says a study.
-
New Oral Pill Enlicitide Cuts 'Bad' Cholesterol By 60% In Landmark Trial
The new oral pill enlicitide cuts bad cholesterol risk by 60% in a new landmark trial. Here are the mechanisms behind it and why the oral pill could revolutionise cholesterol management.
-
New Experimental Drug Enlicitide May Cut "Bad" Cholesterol By Up To 60%
A new daily oral medication, enlicitide, has shown reductions in LDL cholesterol of up to 60% in a late-stage Phase 3 trial, matching the efficacy of injectable PCSK9 inhibitors.
-
Protein Linked to Heart Attack Identified
A protein that increases levels of LDL (low-density lipoprotein) cholesterol, also referred to as "bad" cholesterol, in the bloodstream is associated with heart attacks, says a study.
